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The Malignant Neuroleptic Syndrome 
(M. N. S.) as a relatively uncommon but 
potentially lethal complication of neuro-
leptic drug treatment was first described 
in the French literature by Delay el al. 
(1960), and several cases of so called 'Malig-
nant Hyperthermia' in relation to neuro-
leptic drug intake were described. It is 
only in the last few years that this syndrome 
has received some attention in the English 
language literature—CarofF (1980) in his 
review states that a total of about 60 cases 
have so far been reported in the world 
literature. Although exact figures of its 
incidence are difficult to obtain, Delay et 
al. (1963) in their series of patients treated 
with haloperidol reported an incidence of 
approximately 0.5% to 1.0%. This would 
suggest that M. N. S. is not as rare as 
generally believed, considering the large 
number of patients being treated with 
neuroleptics, but that probably many cases 
are not recognised as such and hence go 
unreported. 
Clinical features : 
The Malignant Neuroleptic Syndrome 
is characterised by :— 
(a) A rise of body temperature—-ranging 
from 38° C (99°F) to as high as 
41°G (106°F). 
(b) Impairment of Consciousness—which 
may vary from a dazed mutism 
through stupor to coma. 
(c) Autonomic Dysfunction—eg. labile 
blood pressure with marked tachy-
chardia, profuse diaphoresis, dys-
pnoea, dysphagia, urinary retention 
or incontinence. 
(d) Neuromuscular Dysfunction mani-
festing as catatonic like rigidity, 
akinesia, dyskinesia, or involuntary 
movements. The ligidity is generally 
described as being of lead pipe or 
plastic type. 
Clinical Course : 
M. N. S. may occur from hours to 
months after the initial exposure to the 
drug but once initiated, signs and symptoms 
develop rapidly over the next 24-72 hours. 
It usually starts with a sudden, unexplained 
rise of temperature with impairment of 
consciousness, followed by the signs of 
neuromuscular and autonomic dysfunction. 
It usually lasts from 5 to 10 days after cessa-
tion of neuroleptic drug therapy ; and if 
detected early and intensive supportive 
therapy instituted, recovery can be expected 
in a majority of cases. 
Of the 60 cases described in the litera-
ture, death occurred in 12 patients, giving 
a mortality rate of 20%- Interestingly, 
6 of these 12 cases were being treated with 
depot fluphenazine preparations. Death, 
when it occurs, is due either to cardio-
vascular collapse or respiratory and/ or renal 
failure. Autopsies performed on these cases 
have revealed only non-specific or secondary 
changes. The apparently increased mor-
tality rate with the long acting fluphenazine 
compounds is probably a function of the 
long half-life of these drugs, and the re-
sulting prolonged exposure to the agent 
even after discontinuing medication. 
Laboratory Investigations : are generally 
within normal limits, but nevertheless are 
necessary to rule out other medical conditions 
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that are to be considered in the differential 
diagnosis. In the literature, leucocytosis 
has been reported in 14 cases, serum C. P. K. 
elevations in 7 cases and non-specific, gene-
ralised E. E. G. abnormalities suggestive 
of a diffuse encephalopathy in 6 cases. 
Treatment : 
The main purpose of therapy is to 
maintain the body temperature, blood 
pressure and fluid and electrolyte balance. 
Thus, optimal treatment consists in early 
recognition, immediate stoppage of all psy-
chotropic medication, and the prompt and 
energetic institution of intensive mediaal 
and nursing supportive care. 
There is no specific treatment known 
that affects either the morbidity or mortality 
of the M. N. S. Anticholinergic drugs have 
been tried but without any success ; besides, 
the very fact that a number of these patients 
were already receiving anticholinergic drugs 
along with the neuroleptic medication, in-
dicates that it is not effective in preventing 
the onset of M. N. S. E.C.T. has been 
used in 2 cases but again the response was 
equivocal. Antibiotics and dialysis are 
useful only in cases who develop secondary 
infection or acute renal failure. 
Differential Diagnosis : 
The acute onset of high grade fever 
with impairment of consciousness invariably 
suggests an acute encephalopathy. The 
common causes that must be excluded are 
viral encephalitis, enteric encephalopathy) 
and cerebral malaria ; although other bac-
terial, fungal, and parasitic infections must 
also be excluded. Some patients with 
marked catatonic rigidity or akinesia may 
resemble an acute post-infectious encephalo-
pathy such as encephalitis lethargica, 
akinetic mutism, or even tetanus. Rarely, 
strychnine poisoning, myotonia, tetany, and 
hysterical conversion symptoms may also 
have to be considered and excluded. 
M. N. S. seems to be clinically dis-
tinct from heat stroke which has also been 
reported as a complication of neuroleptic 
therapy in a hot climate (Itoh et al., 1977). 
On the other hand, there are striking 
similarities between M. N. S. and the 
anaesthetic induced 'malignant hyper-
thermia' but the defective membrane re-
gulations and transport of calcium into 
skeletal muscle cytoplasm in presence of 
inhalation anaesthetics is absent in M.N.S. 
Biology and Predisposing factors : 
All ages and both sexes are affected by 
M. N. S. It is more likely to occur with the 
use of high potency neuroleptics in thera-
peutic doses. Almost half of all the reported 
cases have been related to the use of halo-
peridol, and the remaining cases due to 
piperazine phenothiazines and thiothixene 
—only one case has been reported after the 
use of thioridazine (Haberman, 1978). Cha-
racteristic features of M. N. S. have been 
described following the use of neuroleptics 
in combination with lithium (1 case), and 
antidepressants (2 cases). 
Of the 60 reported cases, only 11 showed 
evidence of identifiable brain disease prior 
to neuroleptic exposure. Clinically, the 
patients had a variety of psychiatric diag-
noses including Manic, Depressive, Schi-
zophrenic and Character Disorders. Neuro-
leptics are necessary but not sufficient in 
themselves to trigger the onset of M.N.S., 
apparently other factors must be opearting 
in the initiation of the syndrome in a sus-
ceptible person, at a particular time in the 
course of neuroleptic therapy. Itoh et al. 
(1977) have suggested that the physiologic 
state of the patient at the time of drug 
exposure such as physical exhaustion, or 
dehydration may be an important additional 
factor in determining the onset of M.N.S. . 
CASE REPORTS : 
Case 1 : 
S. K., 45 years married female was 
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Depressive Psychosis, currently manic. She 
had a history of five previous episodes of a 
similar illness which had been treated 
successfully with drugs. She was put on 
oral neuroleptics, and the dosage was gra-
dually increased. Within a period of seven 
days she responded but she complained of 
mild tremors of hands. Subsequently, the 
tremors increased, in addition she developed 
marked generalised rigidity with impair-
ment of consciousness. She progressed into 
a state of stpuor with gross catatonic features 
and dysphagia, even after discontinuing the 
drugs. For the first time she showed a 
rise of temperature to 102°F without 
apparent cause. Medical opinion was 
sought who kept the possibility of either a 
G.V.A. or viral encephalitis and recom-
mended immediate transfer to the medical 
ward for investigation and management. 
She was put on intensive care with four 
hourly check on vital signs, intake-output 
chart, and continuous I. V. fluids. Decadron 
2 cc and Ampicillin 500 mg were ad-
ministered along with the parenteral fluids. 
Temperature ranged between 99°F to 102°F 
throughout the illness. Patient died on 
evening of 2-3-77 as a result of acute renal 
failure. 
Haemogram, Blood sugar, C.S.F. and 
E.G.G. were within normal limits. Urine 
showed albuminura and Blood urea was 
raised. 
Case 2 : 
J. R. 50 yrs. old, married male was 
admitted with a diagnosis of Manic-
Depressive Psychosis—currently manic. He 
was started on oral neuroleptics and 
gradually the dose was increased. After 
about a weak rise of temperature (102°F) 
with rigors and chills was noticed. With-
in next 24 hrs, patient's B. P. dropped and 
he appeared confused, restless, muttering 
to himself with mild generalised rigidity. 
Medical experts suggested the possibility 
of Enteric Encephalopathy. 
All psychotropic drugs were stopped 
and patient was given Decadron 2 ml. 
stat followed by continuous I. V. drip with 
6-8 ampoules of mephentine in each bottle 
to maintain the blood pressure. He was also 
given Chloromycetin 500 mg I. M. 6 
hourly, along with routine supportive 
therapy. This regimen continued for the 
next 8 days,when he regained full conscious-
ness, temperature returned to normal., and 
BP was maintained between 100-110/ 70-80 
mm Hg without mephentine. Thereafter, 
recovery was rapid and patient was dis-
charged after 14 days. 
Haemogram, urine and stool examina-
tion, Blood urea, G.S.F. were within normal 
range. 
Case 3 : 
M. D. a 41 years married female, was 
admitted with a diagnosis of Manic Depres-
sive Psychosis, currently depressed. She was 
put on antidepressants and phenothiazines. 
After 6 days she was noted to have a mild 
temperature for which Paracetamol was 
prescribed. However the fever did not 
subside and by next morning it had risen 
to 102°F. and the patient appeared drowsy 
and unresponsive. The medical consultant 
could not reach to any definite diagnosis. 
She was comatosed and her BP was very 
low. All psychotropic drugs were imme-
diately withdrawn. Decadron 1 ml 6 
hourly, with 4-6 ampoules of mephentine 
in each bottle of I.V. fluids was given to 
maintain the blood pressure. This regime 
was continued for the next 2 days when 
she regained full consciouness & her B.P. 
was stable. Since she was still anxious 
and depressed, she was restarted on anti-
depressants and haloperidol, without any 
adverse effects. Subsequently she was 
discharged. 
Haemogram, blood urea, urine culture, 
C.S.F. were within normal limits. 182  GURMEET SINGH 
DISCUSSION 
Having seen two patients (cases 2 & 
3) within a period of eight months in which 
a physically healthy person, while under 
treatment with neuroleptics, suddenly deve-
lops an unexplained fever associtaed with 
impairment of consciousness and a severe 
and prolonged fall in blood pressure ; 
alerted us to the possibility that this may 
be a complication of neuroleptic drug use. 
A review of our records revealed one more 
case who had died from a similar unex-
plained illness two yars earlier (case 1). 
Thus, over the past six years, i.e. from 
1974—1980, we have had three cases of 
M.N.S. in approx. 1500 patients treated 
with neuroleptics out of a total admission 
of 2782 patients—giving an incidence of 
0.2%. 
While some authors stressed the hyper-
thermia as the predominant presenting 
symptom of these cases (Moyes, 1973, 
Haberman, 1978), others stressed the sudden 
and dramatic occurrence of a catatonic 
stupor with fatal outcome (Regestein et 
al., 1977, Weinberger and Kelly, 1977). 
A majority now consider the simultaneous 
presence of hyperthermia, rigidity, and 
impaired consciousness with autonomic dys-
function as characteristic of the M.N.S. 
(Delay and Deniker, 1952; Allan and 
White, 1972; Meltzer, 1973 ; Powers, 1976; 
Itoh el al., 1977 ; Grunhaus, 1979, Caroff, 
1980). Our patients clearly fulfil these 
criteria for M.N.S. Although no definite 
conclusions can be drawn from three cases, 
it is interesting to speculate that perhaps 
the patients showing marked catatonic symp-
toms represent a more severe and diffuse 
impairment of central neuroregulatory me-
chanisms, as compared to those showing 
hyperthermia and fall in blood pressure— 
in which case the disturbance may be 
limited to these hypothalamic centres, and 
hence a more favourable outcome. This 
would also explain the relatively higher 
mortality reported in patients with so called 
malignant or lethal catatonia, and a more 
favourable outcome in cases of malignant 
hyperthermia. 
Another significant observation made 
in the present series of cases is that all 
three patients were receiving butyro-
phenones. This is in line with previous 
reports that M.N.S. is more likely to occur 
on exposure to the potent neuroleptics, 
especially haloperidol or the long acting 
fluphenazine. Apparently this reaction to 
the neuroleptic drug is of an allergic nature 
and not dose related. 
This is the first report of M.N.S. from 
India, and the purpose of this communica-
tion is to highlight the clinical presentation 
of this syndrome so that clinicians are alerted 
to the possibility of this complication in 
their patients receiving neuroleptics. Perhaps 
other psychiatrists will be moved to report 
their experience of this reaction, and hope-
fully, future studies on a larger sample 
will give us a more accurate estimate of the 
incidence of this complication ; and also 
help to elucidate the various possible factors 
operating in its etiology and prognosis. 
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